M&A · Healthcare · Pharmaceutical Preparations
XenoTherapeutics to acquire ESSA Pharma Inc.
Announced Jul 14, 2025 · Closed Oct 9, 2025
Deal value$85M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$1.91 per share
Transaction
- Acquirer
- XenoTherapeutics
- Target
- ESSA Pharma Inc. (EPIX)
- Buyer type
- Strategic
- Offer price per share
- $1.91
- Enterprise value
- —
- Status
- Closed Oct 9, 2025
Deal protections
- Break fee (target pays)
- $2.5M · 2.9%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 94 in the prior 24 months
- Premium
- Sector median 66.5%
- EV / Adj. EBITDA
- Sector median 13.8x
- Break fee
- 2.9% vs. 3.5% sector median
Timeline
- AnnouncedJul 14, 2025
- Proxy filedJul 30, 2025
- Definitive proxyAug 11, 2025
- Shareholder voteOct 3, 2025
- ClosedOct 9, 2025